Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Media

AIM Rule 26

Regulatory news

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Building on our previous discussions on RNA therapeutics and their potential, this episode explores one of the biggest hurdles in drug development—getting RNA to the right cells safely and effectively.

CEO Nigel Theobald breaks down the key barriers to RNA drug delivery, including:

RNA’s vulnerability to degradation in the body, requiring a protective delivery system.

The challenge of cell uptake, as negatively charged RNA naturally repels from cells.

The need to escape the endosome—a crucial step to ensure RNA reaches its target inside the cell.

The lack of targeting ability, meaning RNA can end up in the wrong cells, leading to unintended effects.

The added difficulty of oral delivery, where traditional lipid and viral-based systems face major limitations.

These challenges have driven the demand for a better RNA delivery platform—one that is targeted, non-toxic, effective, and potentially suitable for oral administration.

In our next episode, we’ll explore how Nuvec® has been designed to overcome these barriers and why it could become the delivery platform of choice for RNA therapeutics.

Watch now and submit your questions below.

The Challenges of RNA Delivery